ProCE Banner Activity

ExpressPoints
Next-Generation Therapeutic Strategies for Relapsed/Refractory Multiple Myeloma: Targeting BCMA

Slideset Download

Gain key clinical insights fast, with this short slideset from CCO on key considerations for optimal use of anti-BMCA therapy for patients with relapsed/refractory multiple myeloma.

Released: October 05, 2021

Expiration: October 04, 2022

No longer available for credit.
Begin Activity

Share

Faculty

Suzanne Lentzsch

Suzanne Lentzsch, MD, PhD

Director, Multiple Myeloma and Amyloidosis Program
Associate Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York

Sagar Lonial

Sagar Lonial, MD, FACP

Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Thomas G. Martin

Thomas G. Martin, MD

Associate Clinical Professor of Medicine
Associate Director
, Myeloma Institute
University of California, San Francisco Medical Center
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

GlaxoSmithKline

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Faculty Disclosure

Primary Author

Suzanne Lentzsch, MD, PhD

Director, Multiple Myeloma and Amyloidosis Program
Associate Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York

Sagar Lonial, MD, FACP

Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Thomas G. Martin, MD

Associate Clinical Professor of Medicine
Associate Director
, Myeloma Institute
University of California, San Francisco Medical Center
San Francisco, California